A research team has introduced a novel cancer immunotherapy strategy. This approach involves attaching "fake targets" to ...
Belantamab mafodotin provides a community-friendly BCMA-directed therapy option for relapsed/refractory myeloma, says Hearn ...
It's been a roller coaster ride for the drug ever since it was granted accelerated approval in 2020 for the treatment of ...
Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, ...
Two teams of researchers have developed a cell reprogramming technology that converts rogue disease-causing T cells from our ...
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
(NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in ...
Antigen Security, LLC ("Antigen") in partnership with Cloud 9 Computing Group, a leader in managed IT and technology ...
Producers face decisions that could mean the difference between manageable losses and significant mortalities.
Countries straining to contain a second wave of COVID-19 are turning to faster, cheaper but less accurate tests to avoid the delays and shortages that have plagued efforts to diagnose and trace those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback